Promatix Biosciences Presents Positive Preclinical Data with First-in-Class PBS293 EGFR×EphA2 Cis-Bispecific ADC Demonstrating Enhanced Tumour SelectivityLondon and Cambridge, UK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Promatix Biosciences Ltd (Promatix), an emerging UK-based biotechnology company developing innovative new classes of cancer therapies using cis-bispecific antibodies, today presented positive preclinical data at the 16th World ADC London Summit on its lead molecule, PBS293-MMAE, a first-in-class bispecific ADC for colorectal cancer.
